Rationale: GSK-3β (glycogen synthase kinase 3β) is a multifunctional and constitutively active kinase known to regulate a myriad of cellular processes. The primary mechanism to regulate its function is through phosphorylationdependent inhibition at serine-9 residue. Emerging evidence indicates that there may be alternative mechanisms that control GSK-3β for certain functions.
G SK-3β (glycogen synthase kinase 3β) is a multifunctional serine/threonine kinase found in all eukaryotes that is involved in regulating a wide range of cellular processes. Dysregulation of GSK-3β is implicated in many human diseases, including heart disease, diabetes mellitus, Alzheimer disease, bipolar disorder, and cancer. [1] [2] [3] The enzyme is a constitutively active negative regulator of glycogen synthesis, translation initiation, Wnt signaling, Jun proto-oncogene, nuclear factor of activated T-cells transcriptional activation, and microtubule-associated protein tau kinase activity. 2, 4 Relief of downstream pathway inhibition, for example, the activation of glycogen synthesis, occurs mainly through phosphorylationdependent inhibition of GSK-3β activity. Phosphorylation of GSK-3β at its serine-9 residue (pSer-9) by activated Akt occurs in response to insulin receptor signaling. 2, 5, 6 Although GSK-3β can be phosphorylated at Thr43 and Ser389/Thr390 by ERK (extracellular signal-regulated kinase) and p38 MAPK (mitogen-activated protein kinase) respectively, they serve to further enhance pSer-9-dependent inhibition rather than promote a direct inhibition of its kinase activity. 7, 8 The regulation of β-catenin degradation by GSK-3β is one exception to the phospho-inhibition paradigm. In this case, GSK-3β activity proceeds regardless of the pSer-9 state, because of the formation of a protein-protein complex with axin and β-catenin. 2 Over the past 2 decades, GSK-3β has emerged as a therapeutic target. Inhibiting GSK-3β activity through pharmacological intervention has become an important strategy for the treatment of numerous disease conditions, 3, 9 some of which have been tested in clinical trials. 10 However, these strategies
have not yet become routinely used. Only lithium, a GSK-3 inhibitor, is currently in clinical use for treatment of bipolar disorders. However, only ≈30% of patients can be considered full responders, 11 indicating the complexity of GSK-3β regulation. Furthermore, constitutively active GSK-3β (Ser9Ala) mutant knockin mice have only a subtle defect related to insulin regulation of glycogen synthase in skeletal muscle tissue. 12 Taken together, this suggests that regulation other than phosphorylation may be involved in controlling of GSK-3β for certain functions.
Nitric oxide (NO) is now a well-recognized player in maintaining cardiovascular function. One mechanism of this is achieved through the classic NO/soluble guanylyl cyclase (sGC)/cGMP (cyclic guanosine monophosphate)/PKG (protein kinase G) signaling pathway. 13, 14 However, NO-mediated protein S-nitrosylation (SNO) has been recently shown to play an essential role in cardioprotection, which is at least partly cGMP-independent against ischemia-reperfusion injury. 15 NO-mediated protein SNO is now recognized as a fundamental signaling mechanism to alter protein conformation, enzymatic activity, protein-protein interaction, and cellular localization. 16, 17 SNO modification has also been proposed to protect against more irreversible cysteine oxidation that can occur in heart disease. 17, 18 Our previous study demonstrated that GSK-3β reactivation through cardiac resynchronization may restore myofilament calcium sensitivity in heart failure (HF) to enhance contractile function. 19 Here, we report a novel pSer-9-independent mechanism to regulate GSK-3β function via protein SNO at multiple Cys residues that inhibits GSK-3β activity. Importantly, an additional novel effect of SNO was found that overrides the effect of pSer-9 by driving GSK-3β nuclear localization and downstream gene activation.
Methods
All data and materials of the article have been made publicly available at PeptideAtlas and can be accessed at http://www.peptideatlas. org/PASS/PASS00968.
Animal Model and Sample Preparation
Guinea pig HF model was established by combining ascending aortic constriction and daily isoproterenol administration as described previously. 20 At the terminal time point of the study, the hearts were excised and retrogradely perfused to remove blood using normal Tyrode's solution briefly followed by perfusion with 10 mL ice-cold Cys modifications and phosphorylation preservation buffer. 18 Tissue samples obtained from the left ventricle were quickly excised and immersed in the same buffer and minced into small pieces and snap-frozen in liquid nitrogen and then stored at −80°C until use.
Detection of Protein SNO
S-nitrosocysteine (CysNO) was freshly prepared for each use, as described. 21 Protein SNO was detected using biotin switch assay, as described previously 22 and modified by our group. 21 To identify Snitrosylated amino acid residues, resin-assisted capture protocol was adopted and done as described. 
Novelty and Significance
What Is Known?
• GSK-3β (glycogen synthase kinase 3β) is a multifunctional kinase involved in multiple cellular processes and plays critical roles in heart failure (HF).
• GSK-3β is functionally regulated by phosphorylation of serine 9 residue via growth factors such as insulin and the PI3K/AKT pathway.
• Nitric oxide (NO) is a signaling molecule that can alter protein function via protein cysteine posttranslational modification (S-nitrosylation) or soluble guanylyl cyclase/PKG (protein kinase G) pathway, which has roles in HF.
What New Information Does This Article Contribute?
• GSK-3β can be regulated by S-nitrosylation independent of its phosphorylation state (pSer-9) and the classical NO/soluble guanylyl cyclase/PKG (protein kinase G) pathway.
• Quantitative phosphoproteomics analysis led to the identification of 300 GSK-3β substrates that were differentially regulated by phosphorylation and S-nitrosylation.
• NO signaling promotes nuclear translocation of GSK-3β and activates a nuclear signaling network that includes RNA posttranscriptional regulation and DNA repair.
• Inhibition of GSK-3β S-nitrosylation is associated with progression of HF in a guinea pig model of HF and sudden cardiac death.
The present study reveals a novel mechanism of GSK-3β mediated by NO signaling that is independent of classical regulation by phosphorylation. NO signaling fine-tunes GSK-3β to modulate a subset of its targets. We identify SMC-1A (structural maintenance of chromosomes protein 1A), a DNA repair protein, as a potential nuclear substrate of GSK-3β. NO modification induces a novel pattern of GSK-3β substrate phosphorylation both in the cytoplasm and nucleus. These findings represent potentially new therapeutic targets for diseases in which GSK-3β has been implicated, including HF.
Label-Free Quantitative Phosphoproteomics
Total cell lysates (250 µg−1 mg) or isolated nuclear fraction (1 mg) were reduced and alkylated, and then digested with trypsin and desalted with Oasis HLB cartridges (Waters) following the manufacturer's protocol. Phosphopeptides were enriched with Titansphere Phos-TiO kit (3 mg/200 µL spin column, GL Sciences) according to the manufacturer's protocol. The enriched phosphopeptides were then dried down under vacuum for label-free mass spectrometry analysis. The MS/MS (mass spectrometry/mass spectrometry) proteomics data have been deposited to the PeptideAtlas (http://www.peptideatlas. org/PASS/PASS00968) 24 with the data set identifier PASS00968.
Amino Acid Motif Analysis
GSK-3β consensus motifs with flanking sequence were generated using the Protein Sequence Motif Extractor tool available at the PNNL (Pacific Northwest National Laboratory) and the OMICS.PNL.GOV website. PhosphoSitePlus Logo Generator was used to analyze the unique phosphopeptides that showed a 2-fold or more increase in phosphorylation across the 3 conditions: Phos Inhibition, SNO inhibition, and SNO activation from the HEK (human embryonic kidney) nuclei data set (http://www.phosphosite.org/sequenceLogoAction.do).
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Protein Network Analysis
The downstream bioinformatics analysis of the mass spectrometrygenerated proteomics data sets used system biology tools including Cytoscape v3.3.0 26 and the Reactome functional interaction (FI) plugin (database 2015) 27 for analyses presented, and the proteomics data were overlaid with biological annotations using Cytoscape. Gene ontology (GO) enrichment analysis was completed using the Cytoscape app BiNGO 28 and REVIGO, 29 to analyze the biological process, cellular component, and molecular function.
Statistics
All protein data are expressed as means±SD. Independent groups were compared via unpaired 2-tailed Student t test with P<0.05 being considered significant.
Results
Dynamic SNO at Multiple Cys Residues Regulates GSK-3β Function
To map the proteins that are S-nitrosylated targets in the heart, we undertook extensive redox proteomic analysis of enriched rat heart myofilament fraction 19 (n=4) treated with the NO donor S-nitrosyl glutathione (100 µmol/L for 20 minutes at 37°C) using resin-assisted capture 23 and liquid chromatographytandem mass spectrometry. Three unique tryptic peptides of rat GSK-3β (UniProt Knowledgebase accession number P18266) were identified containing SNO at residues Cys 76, Cys 199, and Cys 317 (Online Table I ; Online Figure IA) . S-nitrosylation of GSK-3β was confirmed in whole rat heart extract, H9C2 cells, a heart-derived myoblast cell line that is used as a cardiomyocyte surrogate 30 and HEK293 cells by the biotin switch method 22 which was followed by Western blot using an anti-GSK-3β antibody (Online Figure IB) . Snitrosylation of GSK-3β was concentration-dependent in HEK293 cells ( Figure 1A and 1B) which was also true for 2 other kinases within the GSK-3β signaling network, Akt and Erk1/2, previously identified as S-nitrosylated targets in cultured skeletal muscle cells 31 and MCF-7 (Michigan Cancer Foundation) cells, 32 respectively. Mono-, di-, and tri-GSK-3β Cys mutants were created where Cys residues (Cys 76, Cys 199, and Cys 317) were replaced with Serine (Ser), rendering them non-S-nitrosylatable. Each mutant was overexpressed under a cytomegalovirus promoter in HEK293 cells. The cells were treated with 100 µmol/L CysNO for 20 minutes, and protein SNO levels were analyzed with the biotin switch protocol. Compared with wildtype GSK-3β, all Cys mutants significantly decreased SNO levels, especially the double or triple mutants ( Figure 1C , upper; Figure 1D ). However, even the triple mutants had low levels SNO compared with mock-treated wild-type GSK-3β. Therefore, single Ser mutant of all 9 Cys residues of GSK-3β was generated and analyzed as above. A total of 6 mutants, including Cys 76, Cys 199, and Cys 317, as well as Cys 178, Cys 245, and Cys 335 also decreased, but did not abolish, GSK-3β SNO level (Figure 1C, lower; Figure 1D ). This suggests that these Cys can act as potential acceptor sites for SNO. Taken together, these results indicate that GSK-3β is S-nitrosylated at multiple Cys residues. These residues are either surface exposed or surrounded by several positively charged residues, based on the crystal structure of human GSK-3β (PDB [Protein Data Bank] ID 1UV5, Online Figure  IC ). These sites should be deprotonated at physiological pH, making them potential candidates for SNO. 17 The ability to S-nitrosylate a protein depends on the accessibility/local environment of its modified residues and the rate of denitrosylation. Denitrosylation is equally important for understanding the duration of the effect of SNO on the function of downstream targets. To investigate the dynamics of SNO/denitrosylation of GSK-3β in HEK293 cells, we evaluated the extent of S-nitrosylation of targets after the removal of the NO donor ( Figure 2A) . SNO levels of all 3 kinases increased and peaked during 20 minutes of treatment with 100 µmol/L CysNO (time 0 minutes in Figure 2A and 2B refers to the onset of CysNO removal from the medium) but sharply decreased at time points >20 minutes after CysNO removal. SNO of GSK-3β completely returned to mock treatment level after 6 hours ( Figure 2A and 2B). This data indicates that S-nitrosylation of GSK-3β, ERK, and AKT are all reversible.
The effect of SNO on GSK-3β kinase activity in the context of GSK-3β signaling network (also AKT and ERK) was determined by site-specific phosphorylation assessment of several well-established substrates (eg, AKT phosphorylates GSK-3α/β at S21/9, GSK-3β phosphorylates Gys-1 (glycogen synthase 1) at S641/645, Erk phosphorylates p90RSK at T573) on CysNO treatment. As shown in Figures 2A and 2B , the classic pSer-9 of GSK-3β was significantly decreased but was not abolished with 100 µmol/L CysNO treatment for 20 minutes. Traditionally, this would imply that GSK-3β would be activated via inhibition of AKT, however, the site-specific phosphorylation level of GSK-3β substrates, Gys-1 at Ser641/645, were significantly decreased ( Figure 2A and 2B). Twenty minutes after removing CysNO, the phosphorylation of AKT, GSK-3α/β, and ERK-1/2 rebounded to supranormal levels, whereas full recovery of Gys-1 phosphorylation was delayed until 6 hours ( Figure 2A and 2B). This indicates that protein SNO reversibly inhibited GSK-3β activity independently of the classic pSer-9 inhibition pathway. Furthermore, the phosphorylation level of Gys-1 is negatively correlated with GSK-3β SNO levels, whether or not the cells were pretreated with AKT inhibitor, MK2206, or AKT activator, IGF-1 (insulin-like growth factor; Figure 2C ; Online Figure IIB ). Note that 100 µmol/L CysNO treatment for Figure 1 . GSK-3β (glycogen synthase kinase 3β) is S-nitrosylated at multiple cysteine (Cys) residues in vitro with NO donor treatment. A, Dose-dependent induction of S-nitrosylation (SNO) of GSK-3β in vitro with S-nitrosocysteine (CysNO) treatment in HEK293 (human embryonic kidney) cells. B, Quantification of (A). SNO level is normalized to the input used for biotin switch assay. Error bars represent SD of 3 independent experiments. *P<0.02 and **P<0.005 vs mock treatment, using unpaired 2-tailed Student t test. C, Sitespecific S-nitrosylation of GSK-3β in HEK 293 cells. Western blots show the extent of SNO modification of GSK-3β for wild-type (WT) and various single, double, or triple GSK-3β Cys mutants after CysNO treatment (100 µmol/L for 20 min at 37°C). D, Quantification of the Snitrosylation level of GSK-3β WT and Cys mutants as shown in the upper of B. SNO levels of each kinase were normalized to their inputs for the biotin switch assay. Error bars represent SD of 3 independent experiments. *P<0.05, **P<0.01, and ***P<0.001 vs WT; ##P<0.002 vs the triple mutant C76S/C199S/C317S, using unpaired 2-tailed Student t test. Figure IIA) . Together, these data confirm that S-nitrosylation inhibition of GSK-3β kinase activity is not dependent on the pSer-9 status. Rather, S-nitrosylation of GSK-3β further enhances inhibition when Ser-9 is already phosphorylated.
hour was chosen based on concentration-responses and time course assays in HEK293 cells (Online
The effect of SNO on GSK-3β kinase activity was further evaluated in the primary neonatal rat ventricular myocytes (NRVM). It is well-known that NO can activate PKG through NO/sGC/cGMP/PKG pathway, 13 which could potentially contribute to GSK-3β phosphorylation inhibition. To find out whether this pathway contributed to the CysNO-induced GSK-3β inhibition, we pretreated the NRVM with DT-3, a potent PKG inhibitor, before CysNO treatment. As above, GSK-3β kinase activity was assessed by the level of phospho-Gys-1 at Ser 641/645, whereas the PKG activity was assessed by the level of phospho-VASP (vasodilator-stimulated phosphoprotein) at Ser 239, a validated PKG substrate. As shown in Figure 2D , and Online Figure IIC , compared with the vehicle treatment, DT-3 pretreatment did not have a significant effect on GSK-3β inhibition, while CysNO-induced strong GSK-3β inhibition, especially at the high dose (100 µmol/L). As a control, 8-BrcGMP, a potent PKG activator, also did not have a significant effect on GSK-3β inhibition, although it did strongly induce VASP phosphorylation compared with vehicle treatment. This result indicates that inhibition of GSK-3β activity by high dose CysNO (100 µmol/L) is because of the SNO-mediated GSK-3β inhibition but not the phosphorylation-mediated GSK-3β inhibition. Interestingly, this high dose of CysNO (100 µmol/L) resulted in phosphorylation of ERK-1/2 in a PKG-dependent manner, as shown by the fact that DT-3 pretreatment abolished this phosphorylation, while it simultaneously inhibited the phosphorylation of GSK-3β (and Akt) in a PKG-independent manner ( Figure 2D ; Online Figure IIC) . It is well-established that PKG can activate MAPK (p38 MAPK and Erk1/2). 33, 34 Thus, a high dose of CysNO might activate PKG even though the phospho-VASP level did not change. Taken together, our data support that NO-activated sGC/ Figure 2 . S-nitrosylation (SNO) reversibly modulates GSK-3β (glycogen synthase kinase 3β) kinase activity independent of pSer-9 status. A, S-nitrosylation of kinases (upper) and phosphorylation status of the kinases and their substrates in response to Snitrosocysteine (CysNO) treatment. HEK293 (human embryonic kidney) cells were serum starved for 18 h and treated with 100 µmol/L CysNO for 20 min. CysNO was then removed (0 min), and fresh medium with serum was added and incubated for 20 min or 6 h. B, Quantification of S-nitrosylated kinases, phosphorylation of kinases, and their substrates from data obtained as in A. C, Quantitative analysis of SNO modification of the kinases and the phosphorylation level of kinases/substrates from data obtained as shown in B. Snitrosylation of kinases was normalized to their inputs for the biotin switch assay. Phosphorylation of kinases/substrates was normalized to their total protein levels in the sample. HEK293 cells were serum starved for 18 h and pretreated with 3 µmol/L MK2206 or 50 ng/mL IGF-1 (insulin-like growth factor) for 1 h to inhibit or activate Akt signaling, respectively. Then CysNO was added to a final concentration at 100 µmol/L and incubated for another 1 h. Error bars represent SD of 3 independent experiments. *P<0.005 vs mock (CysNO absent) in the same pretreatment group, using unpaired 2-tailed Student t test. D, SNO inhibition of GSK-3β kinase activity is independent of NO/soluble guanylyl cyclase (sGC)/cGMP (cyclic guanosine monophosphate)/PKG (protein kinase G) pathway in neonatal rat ventricular myocytes (NRVMs). Quantitative analysis of the phosphorylation level of kinases (right) and substrate (left) from data obtained as shown in Online Figure IIC . NRVM were serum starved for 24 h and treated with vehicle or 1 µmol/L Bay-K 8644, 1 µmol/L auranofin for 1 h, and 100 µmol/L 8-Br-cGMP for 15 min. For CysNO treatment, the cells were pretreated with or without 1 µmol/L DT-3 for 1 h. Then CysNO was added to a final concentration at 10 or 100 µmol/L and incubated for another 1 h. Phosphoprotein level is normalized to its total protein level as relative phosphoprotein level. Error bars represent SD of 3 independent experiments. *P<0.05 and **P<0.005 vs vehicle treatment group, n.s., not significant, using unpaired 2-tailed Student t test.
cGMP/PKG pathway has little effect on SNO-mediated GSK-3β inhibition. This result is similar to published work from Sun et al, 15 which demonstrated that the SNO-induced cardioprotection is independent of the NO-activated sGC/cGMP/ PKG pathway in a well-established mouse preconditioning model.
Furthermore, to establish that S-nitrosylated GSK-3β inhibition can occur through physiological stimuli (ie, Ca 2+ ), NRVM were treated with Bay-K 8644, a calcium channel agonist that can activate NOS activity, and thus promote the endogenous NO production. Bay-K 8644 treatment induced GSK-3β inhibition to a similar extent as that of 10 µmol/L CysNO treatment alone ( Figure 2D ; Online Figure IIC) , consistent with activation of endogenous SNO in NRVM, although other effects could be involved. In addition, when NRVMs were treated with auranofin, a potent inhibitor of thioredoxin reductase, which we hypothesized could be the potential GSK-3β denitrosylase, an increase in endogenous S-nitrosylated GSK-3β was observed, mimicking the effect of the exogenously applied NO donor, CysNO. Auranofin treatment resulted in the most severe GSK-3β inhibition, even higher than exogenously applied 100 µmol/L CysNO-induced S-nitrosylated GSK-3β inhibition ( Figure 2D ; Online Figure  IIC) . Interestingly, Auranofin targets thioredoxin and its reductase to regulate cysteine redox state. The effect of auranofin on GSK-3β function may be partly contributed by other forms of cysteine oxidation, although we did not detect any significant effect when we treated with 1 mmol/L H 2 O 2 for 1 hour in HEK293 cells (data not shown). This result demonstrated that thioredoxin reductase is likely to be the GSK-3β denitrosylase and that blocking denitrosylation significantly inhibits GSK-3β activity, most likely via SNO modulation independent of phosphorylation.
GSK-3β Is S-Nitrosylated In Vivo in an Animal Model of HF
To determine whether GSK-3β SNO can occur in vivo under pathophysiological conditions, we turned to an established guinea pig model of HF. 20 Accordingly, animals underwent ascending aortic constriction and a single low daily dose (1-2 mg/kg) of the β-adrenergic agonist isoproterenol (ACi, n=3-5), which accelerates the progression of HF. 20 Sham-operation (Sham, n=5) or sham-operation with isoproterenol treatment (Shami, n=5) both acted as controls and neither induced hypertrophy or HF. The ACi group at 2 weeks shows compensated hypertrophy with increased heart weight and normal fractional shortening (ACi2W), whereas after 4 weeks, hearts show dilated left ventricle chamber dimensions and decreased fractional shortening, along with clinical signs of end-stage HF (ACi4W). 20 Protein SNO was detected in heart tissue lysates (hearts harvested to preserve SNO modifications 18 ) with the biotin switch assay, followed by Western blot detection ( Figure 3A) . Compared with Sham, S-nitrosylated AKT levels increased in both the Shami and ACi groups, but compared with Shami, only ACi4W-induced significant S-nitrosylation of AKT ( Figure 3B ). In contrast, the Shami group did not induce any significant change in S-nitrosylated GSK-3β level ( Figure 3B) . However, the ACi2W group showed a significant increase in S-nitrosylation of GSK-3β compared with the Shami control group, which further increased in the ACi4W group ( Figure 3B ). This demonstrates that S-nitrosylation of GSK-3β differentially correlates with the development of HF rather than with β-adrenergic agonist treatment itself.
To further evaluate the effect of SNO on GSK-3β activity in concert with developing HF, we examined the phosphorylation status GSK-3β and its upstream kinase AKT, as well as several canonical GSK-3β downstream substrates, Gys-1 and β-catenin. These data were generated in total heart extracts from the same set of samples ( Figure 3A) . AKT phosphorylation at Ser 473 was significantly increased in Shami compared with Sham ( Figure 3C) ; however, this induction was reversed in the ACi4W group. This might be because of the significant SNO inhibition on AKT phosphorylation in ACi4W, supported by the data obtained in an in vitro functional assay ( Figure 2C ). In contrast, in the Shami group, there was no significant change in GSK-3β pSer-9 level, although it was significantly decreased in the ACi4W group, corresponding to the decreased phospho-AKT level ( Figure 3C ). Based on previous dogma, this would imply GSK-3β should be highly activated in the ACi4W group; however, both phospho-Gys-1 and phospho-β-catenin level were significantly decreased compared with the Shami4W control ( Figure 3C ). This indicates that GSK-3β SNO inhibition overrides the expected activating effect of pSer-9 dephosphorylation in end-stage HF. Together, the data suggest that S-nitrosylation of GSK-3β plays a major regulatory role in HF, independent of pSer-9 status.
1,35
Cross Talk Between NO Signaling and GSK-3β Signaling Network
To elucidate the influence of SNO versus pSer-9 status of GSK-3β on its downstream substrates, we performed quantitative phosphoproteomic experiments in HEK293 cells and H9C2 cells ( Figure 4A shows the workflow of the experimental design, data analysis, and inclusion criteria). IGF-1 and MK2206 were used as positive and negative modulators of AKT, respectively, consequently inhibiting or activating GSK-3β kinase activity through pSer-9. CT99021, a highly selective and potent small molecule GSK-3 inhibitor, 36 was used as a negative control for GSK-3 activity for the whole experiment (biological replicates, n=4). The efficacy of the kinase inhibitor treatments was evaluated by a targeted approach with site-specific phospho-antibodies (Online Figure IIIA and IIIB). As expected, CT99021 almost completely abolished GSK-3β kinase activity for the selected targets, Gys-1, β-catenin, and CRMP-2 (collapsin response mediator protein). Whereas, IGF-1 and CysNO-induced significant phosphoand SNO-dependent inhibition, respectively, when compared with the mock treatment and the GSK-3β activating control, MK2206. In total, 151 and 148 unique GSK-3β substrate proteins were identified from HEK293 and H9C2 cells, respectively (based on the stringent selection criteria; Online Figure  IVA , Online Methods, Online Tables II and III) . There were 3 subpopulations of GSK-3β downstream substrates depending on its posttranslational modification (PTM) status (pSer-9, SNO, or both). In HEK293 cells, of the 151 GSK-3β phosphosubstrates identified, 46 (30.5%) underwent GSK-3β pSer-9-dependent inhibition only (Phos_inhibition), 26 (17.2%) targets showed GSK-3β SNO-dependent inhibition only (SNO_inhibition), and 79 (52.3%) displayed both GSK-3β pSer-9 and SNO-dependent inhibition (Phos-SNO_inhibition; Figure 4B ). H9C2 cells had a similar profile, with a slightly higher number (from 17.2% to 28.4%) of SNO-inhibition substrates ( Figure 4B ). Collectively, these data indicate that GSK-3β substrates are differentially regulated by SNO and phosphorylation. Furthermore, a subset of these substrates is regulated through an SNO-dependent GSK-3β pathway.
GO enrichment analysis (biological process) of the 148 GSK-3β phosphosubstrates identified in H9C2 cells was performed using the Cytoscape application BiNGO (Online Table IV ) and was followed by the reduction and visualization of the enriched GO using REViGO ( Figure 4C ). The GO enrichment analysis revealed that cytoskeleton organization (blue, Figure 4C ), regulation of Ras protein signal transduction (green, Figure 4C ), and regulation of microtubule-based processes (pink, Figure 4C ) were top biological process for GSK-3β downstream substrates, whereas protein transport and transcriptional regulation dominated the SNO-dependent GSK-3β regulation (Online Table IV ). To more extensively characterize the effect of GSK-3β PTM on its downstream signaling network, the 151 GSK-3β substrates identified from HEK293 cells were analyzed via Reactome FI in Cytoscape. The Reactome map ( Figure 4D ) consisted of 156 nodes with 35 linker genes and 120 observed candidates. Thirty-six nodes were Phos-inhibition targets, 61 were Phos_SNO-inhibition, and 23 were SNO-inhibition. A pathway enrichment analysis of the interactome emphasized that cell cycle, adherens junction, PI3K signaling events, and regulation of the PTM, SUMO (small ubiquitin-like modifier), were the top hits (Online Table IV for a full list of enriched pathways).
To minimize any indirect biased interaction because of the addition of linker genes, we also mapped the interactions without linkers (Online Figure IIIC) . The resulting network was highly enriched in cell cycle control signaling pathways, especially for the transition between different stages of cell mitosis (Online Table IV ). Interestingly, a recent study reveals that loss of adult cardiac myocyte GSK-3 leads to mitotic catastrophe, resulting in HF. 37 GO cellular component analysis (Online Table IV ) revealed that the majority of the 50 clustered targets are localized in, or are associated with, the nucleus, suggesting that NO signaling preferentially regulates nuclear-localized GSK-3β substrates. Taken together, our global phosphoproteomic approach revealed NO signaling cross talk to the GSK-3β kinase signaling network to produce complex interaction dynamics involving cell cycle control, transcriptional regulation, and protein PTMs that are traditionally involved in the regulation of nuclear signals (eg, SUMO).
SNO Induces GSK-3β Nuclear Translocation
GSK-3β has a well-characterized bipartite nuclear localization sequence which can direct its translocation to the nucleus under certain conditions, 38 although, how nuclear import is regulated remains poorly understood. 39 To investigate whether SNO could directly induce GSK-3β nuclear translocation, we initially performed subcellular fractionation after SNO induction and detected S-nitrosylated GSK-3β with biotin switch and Western blot in both HEK293 and H9C2 cells. As shown in Figure 5A , SNO-GSK-3β is specifically enriched in the nuclear fraction (circled bands) as compared with the cytoplasmic GSK-3β pool with 100 µmol/L CysNO treatment for 20 minutes.
To confirm the SNO-induced GSK-3β nuclear translocation, we developed a novel GSK-3β nuclear activity reporter system (Online Figure IVA) . Specifically, we fused the gene fragment encoding the GSK-3β phosphorylation sites from human Gys-1 to a nuclear localization sequence and overexpressed it in HEK293 cells with either an myc/FLAG-or GFP (green florescent protein)-tag, thus creating an artificial GSK-3β substrate localized exclusively to the nucleus (Online Figure IVB) as a measurement of nuclear GSK-3β activity. We rationalized that if SNO induces GSK-3β nuclear translocation, then phosphorylation of the reporter by GSK-3β will resist SNO inhibition as compared with its native counterpart, that is, cytoplasmic Gys-1. As expected, the endogenous pGys-1 level decreased significantly with CysNO treatment compared with the positive control (MK2206 treatment) with CysNO concentrations larger than 50 µmol/L ( Figure 5B ; Online Figure IVC) , verifying direct SNO inhibition of GSK-3β. The phosphorylation level of the reporter was detected with the same pGys-1 (S641/645) antibody, and it remained higher than the positive control with 20 µmol/L CysNO. In fact, this phosphorylation level was much higher than the endogenous pGys-1 when the Figure 5 . S-nitrosylation (SNO) induces GSK-3β (glycogen synthase kinase 3β) nuclear translocation. A, Subcellular fractionation blot showing that SNO induces GSK-3β translocation to the nuclear fraction and that nuclear GSK-3β is S-nitrosylated. Circled bands corresponding to S-nitrosylated GSK-3β. B, Quantification of the phosphorylation of the GSK-3β nuclear activity reporter and the native GSK-3β substrate pGys-1 (glycogen synthase 1) as represented in Figure S4C . Phosphorylation level was normalized to its corresponding total protein level in the sample. Error bars represent SD of 3 independent experiments. **P<0.01 and ***P<0.001 vs pGys-1 with the same dose of NO treatment, using unpaired 2-tailed Student t test. May 25, 2018
CysNO concentration was >50 µmol/L. This suggests that the effect of GSK-3β nuclear translocation is dominant when the CysNO is <50 µmol/L, whereas SNO inhibition of GSK-3β-mediated phosphorylation is dominant only when the CysNO concentration is >50 µmol/L.
Nuclear-Localized SNO GSK-3β Targets Posttranscriptional Reprogramming and DNA Damage Response
To determine the kinase-substrate interaction network induced by S-nitrosylated GSK-3β within the nucleus, we performed phosphoproteomics on nuclear-enriched samples (biological replicates, n=3; technical replicates, n=2). The nuclear-enriched samples were obtained by using subcellular fractionation after harvesting the cells after different treatments. This was an efficient way to increase the coverage for low abundance proteins. Based on previous inclusion criteria, 138 of the identified 245 GSK-3β nuclear substrates (contain 334 phosphopeptides in total) were defined as GSK-3β Phosinhibition substrates, whereas 166 were exclusive to SNOinhibition substrates and 47 are SNO-activation substrates (Online Table V ). As shown in Figure 6A , 76 GSK-3β substrates undergo both Phospho-inhibition and SNO-inhibition (Phos_SNO-inhibition). Twenty-six substrates underwent both Phospho-inhibition and SNO-activation (Phos-inhibition/ SNO-activation). The dominant biological process (based on BiNGO/REViGO) within the 245 uniquely identified GSK-3β nuclear substrates were centered on RNA processing (blue, Online Figure VA) , chromosome organization (green, Online Figure VA) , and cellular response to DNA damage stimulus (cyan, Online Figure VA) . Similarly, pre-mRNA splicing, transcriptional regulation, and cell cycle control were identified as the top biological pathways among the GSK-3β nuclear interaction network (using Reactome FI informatics with pathway enrichment; Figure 6B ; Online Table VI ). There are striking differences in the subgroups of proteins that were phosphorylated differentially based on the PTM status of GSK-3β within the nuclear enrichment (based on BiNGO/REViGO; Online Table VI; Online Figure VA and VB) . Collectively, the SNOdependent GSK-3β nuclear substrates dominate in RNA splicing (green, Online Figure VB) , whereas SNO-activated nuclear GSK-3β substrates were implicated in the DNA damage response (DDR) pathway (Online Table VI) .
GSK-3β has been implicated in mRNA splicing; specifically, the mRNA splicing factor SC35 40 and PSF (partner of Sld five) 41 regulate the alternative splicing of Tau and CD45, respectively. Although these factors were not observed in our MS data set (probably because the phosphorylation sites for these proteins are not in an MS-friendly tryptic peptide), we did find other splicing factors such as SCAF1, SF3B1, SRSF2, SRSF4, SRSF11, as well as other critical components of RNA splicing, such as NONO (non-POU domain-containing octamer-binding protein), CSTF2 (cleavage stimulation factor subunit 2), CDC40 (cell division control protein), as GSK-3β substrates ( Figure 6B ). Indeed, tandem affinity purification (TAP)-mass spectrometry from the gene-edited GSK-3β cell line that incorporated a TAP tag (see below) identified spliceosome C complex as the major immune protein complex associated with GSK-3β in the nuclear fraction. This is in striking contrast to the APC (adenomatous polyposis coli protein)-axin complex that coimmunoprecipitates with GSK-3β from the cytosolic fraction (data not shown). Taken together, this data provides further support that the nuclear GSK-3β is a key regulator of the RNA splicing machinery for posttranscriptional reprogramming in response to DNA damage.
Unexpectedly, the majority (310 out of 334; Online Table  V) of the identified nuclear GSK-3β substrate phosphopeptides lacked the priming phosphorylation that is typically required for this kinase 42 (pS/TXXXpS/T). This discrepancy in the GSK-3β phosphorylation consensus sequence may be because of an SNO-induced GSK-3β conformational change that leads to the loss of structure-based recognition of the priming site. 2, 43 Moreover, the data reveals that GSK-3β kinase might have evolved other, previously unknown, mechanisms for substrate recognition. Importantly, there is a specific S/T-P motif overrepresented for GSK-3β nuclear phosphosubstrates found in the 435 phosphorylation sites identified from the nuclear proteome (Online Figure VC) . This new substrate recognition pattern for nuclear GSK-3β may be dominant only when the kinase is S-nitrosylated, even though the kinase still retains its classic proline-directed phosphorylation characteristics. Indeed, by examining the known GSK-3β substrates listed in Sutherland 42 and Kaidanovich-Beilin and Woodgett, 44 we found that GSK-3β substrate phosphorylation sites that lack priming phosphorylation still contain the S/T-P motif (Online Figure VD) . Interestingly, the majority of these sites are found on nuclear proteins (Online Figure VD) . Taken together, the data suggest that SNO controls both GSK-3β subcellular localization and a change in GSK-3β substrate specificity.
SMC-1A Is an In Vivo Substrate of GSK-3β in the Nucleus Involved in the DDR Pathway
As the DDR pathway was implicated, we chose to further study SMC-1A (structural maintenance of chromosomes protein 1A), a key component of the cohesin complex that is required for maintenance of sister chromatid cohesion and the DDR pathway. 45 The rationale is that (1) SMC-1A was found to be phosphorylated by GSK-3β at Ser 966 based on our data (Online Tables II and VI) , (2) phosphorylation of SMC-1A by ATM (ataxia telangiectasia mutated) kinase was recently shown to occur on ionizing irradiation, 46 and (3) the pSer-966 antibody of SMC-1A is well-validated and extensively used. As shown in Figure 7A , the phosphorylation of SMC-1A at Ser 966 was induced by CysNO treatment in a concentrationdependent manner in HEK293 cells with the site-specific phospho-antibody, whereas the phosphorylation of Gys-1 at Ser 641 only showed SNO inhibition. Compared with mock treatment, both IGF-1 and CT99021 decreased the phosphorylation level ( Figure 7A and 7B) , confirming that the phosphorylation event is GSK-3 specific. Because SMC-1A Ser 966 is also a well-established target for ATM kinase, to determine which specific kinases regulate the phosphorylation of this residue, kinase-specific inhibition assays were performed ( Figure 7C ). Both CT99021 and Ku55933, a specific ATM kinase inhibitor, significantly suppressed the CysNO-induced phosphorylation of SMC-1A at Ser 966 ( Figure 7C , arrow at ≈180 kDa). Interestingly, there were 2 immune-reactive bands in a high molecular weight range ( Figure 7C , arrowed at ≈350 kDa) that responded to different degrees to the 2 inhibitors. CT99021 almost abolished the phosphorylation of SMC-1A, whereas Ku55933 had no or minimal effect on the phosphorylation ( Figure 7C, arrowed 350 kDa) . These high molecular weight bands are SMC-1A-specific as RNAi significantly knocked down the intensity of the proposed SMC-1A bands, as compared with the scrambled RNA control in HEK293 cells (Online Figure VIA) . . GSK-3β (glycogen synthase kinase 3β) nuclear kinase-substrate network. A, Venn diagram showing the distribution of nuclear GSK-3β substrates from HEK293 (human embryonic kidney) cells. B, Interactome analysis of nuclear GSK-3β phosphosubstrates from HEK293 cells. All candidates, together with GSK-3β itself, were uploaded simultaneously into Cytoscape Reactome FI (functional interaction), only clustered candidates are shown. Phos_inhibition, GSK3β substrates undergo pSer9-dependent inhibition only; SNO_inhibition, GSK3β substrates undergo SNO-dependent inhibition only; SNO_activation, GSK3β substrates undergo SNOdependent activation only; Phos _inhibition-SNO_activation, GSK3β substrates undergo both pSer9-dependent inhibition and SNO-dependent activation.
It is feasible that, as a genotoxic agent, NO could induce DNA damage. In fact, there is a dose-dependent induction of the hallmark of DNA damage, γH2AX, as well as the activation of ATM kinase ( Figure 7B ). However, this was not attributable to a burst of peroxynitrite, as pretreatment with MnTBAP, a peroxynitrite scavenger, had no effect on the activation of SMC-1A and ATM kinase (Online Figure VIB) . Furthermore, our proteomic data shows that CysNO treatment activates GSK-3β and results in the phosphorylation of critical components of checkpoint activation and the DDR pathway, such as MDC-1 (mediator of DNA damage checkpoint protein 1), XRCC-1 (X-ray repair cross-complementing protein 1), ATRX (alpha-thalassemia/mental retardation syndrome non-deletion type x-linked), as well as SMC-1A ( Figure 6B ). Importantly, GSK-3β and ATM kinase compete to phosphorylate the same residue (Ser 966) of SMC-1A, yet they may transduce different functions. GSK-3β cross talk with ATM kinase could coordinate DDR with an NO insult. Finally, using CRISPR/Cas9 gene editing, we created the carboxy-terminal TAP-tagged GSK-3β under its native genetic environment in HEK293 cells to determine GSK-3β binding partners. The TAP-tagged GSK-3β bound SMC-1A (identified by co-immunoprecipitation and Western blot, Figure 7D , as well as by TAP-MS, data not shown) and importantly, CysNO increased the amount of SMC-1A within the protein complex. Taken together, our data support SMC-1A as an in vivo substrate of GSK-3β in the nucleus.
Discussion
The major findings of this study are that (1) S-nitrosylation of GSK-3β can inhibit its activity independent of the canonical PI3K-AKT-dependent pSer-9 mechanism and independent of the classical NO/sGC/cGMP/PKG pathway, (2) SNO induces nuclear GSK-3β localization, and (3) nuclear S-nitrosylated GSK-3β enhances phosphorylation of nuclear targets which are enriched in a unique amino acid consensus sequence, despite inhibition of cytosolic substrate phosphorylation. Specifically, we demonstrate that GSK-3β can both undergo site-specific SNO in vitro, in the presence of an NO donor, and in vivo, through manipulation of the endogenous NO production. We also showed that endogenous S-nitrosylated GSK-3β increases in vivo in a pressure overload-induced animal model of HF. We further report the first quantitative phosphoproteomic data set describing both the global and nuclear GSK-3β kinase-substrate interaction networks, revealing hundreds of novel GSK-3β phosphosubstrates. Some of these are unique to phosphorylation or SNO regulation indicating 2 independent GSK-3β pathways. 1A is GSK-3β dependent. C, Kinase inhibitor assay showing that both ATM (ataxia telangiectasia mutated) and GSK-3β kinases can phosphorylate Ser966 of SMC-1A, whereas induction of phosphorylated high molecular weight product of SMC-1A is specific to GSK-3β. D, Co-immunopurification experiment showing that SMC-1A is physically associated with GSK-3β in HEK293 cells. Tandem affinity purification (TAP)-tagged native GSK-3β was created in HEK293 cells using CRISPR/Cas9 as described in Online Methods. Total cell lysates were used for Co-immunopurification.
Thus, our data strongly suggest that SNO-dependent GSK-3β regulation is critical in cell cycle control, transcriptional and posttranscriptional regulation, and the DDR pathway. We propose a working model for GSK-3β action under nitrosative stress in Figure 8 . We think that SNO-dependent GSK-3β regulation results in spatial and temporal modulation of GSK-3β function independent of the phosphorylation inhibition pathway.
NO donor treatment increased S-nitrosylated GSK-3β, as well as S-nitrosylated AKT and S-nitrosylated ERK1/2, in a concentration-and time-dependent manner. Interestingly, nuclear translocation was induced by SNO only for GSK-3β. Although previous studies have reported that GSK-3β has multiple cellular locations, including the cytosol, mitochondria, and nucleus, 38, 47 the mechanism of translocation between different cellular compartments remained elusive. In addition to demonstrating increased nuclear localization of S-nitrosylated GSK-3β by subcellular fractionation, we also confirmed that GSK-3β activity was increased using a novel GSK-3β nuclear activity reporter system. Finally, using quantitative phosphoproteomics, we showed nuclear enrichment of phosphorylated targets. Together, these data demonstrate that protein SNO directs GSK-3β nuclear translocation, which we suggest could occur through SNO-induced protein conformation change.
Our global, as well as nuclear-enriched phosphoproteomic methods revealed that there is a subset of GSK-3β substrates that are selectively affected by SNO-dependent GSK-3β regulation, whereas other targets are modulated by both mechanisms. This type of cross talk between 2 different types PTMs is a compelling example of a complex regulatory network with characteristics of dynamic code. 16 For instance, GSK-3β-mediated phosphorylation of O-GlcNAc transferase impacts O-GlcNAc transferase-mediated O-GlcNAcylation to fine-tune the circadian clock. 48 Here, we extend this concept by proposing that the interplay between protein SNO and phosphorylation controls the kinase-substrate signaling network. NO signaling, while mainly inhibiting cytosolic GSK-3β targets, led to increased phosphorylation of nuclear targets, whereas AKT-mediated GSK-3β phospho-inhibition should primarily impact cytosolic GSK-3β substrate network.
The SNO-dependent GSK-3β substrate network seems to be highly enriched in cell cycle control proteins. The involvement of GSK-3β in cell cycle control has been described previously and occurs through the regulation of key components in this biological process, such as Cyclin D1, 49 CDC25A, 50 p21cif, 51 and p27kip. 52 Zhou et al 37 also observed high enrichment of differentially expressed genes related to cell cycle and checkpoint activation in cardiac-specific GSK-3α/β double knockout mice. Taken together, these data support our proteomic finding that cell cycle control dominants the SNOdependent GSK-3β substrate network. Moreover, the nuclear Figure 8 . A working model of the pivotal role of NO on GSK-3β (glycogen synthase kinase 3β) function. Based on our data in this study, we hypothesis that NO can induce S-nitrosylation (SNO) of GSK-3β which significantly inhibit its kinase activity, whereas Snitrosylated GSK-3β promote its nuclear translocation where it can interact with splicing machinery to coordinate DNA damage response (DDR) and cell cycle regulation.
